ClinicalTrials.gg
TerminatedNCT05921760Updated Apr 20, 2026Results posted

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

A Phase 1/2 interventional study of Ivosidenib and Nivolumab in IDH1-mutant Cholangiocarcinoma, sponsored by Servier Bio-Innovation LLC. Terminated at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Servier Bio-Innovation LLC · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The sponsor decided to terminate the study during the safety lead-in phase.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
7
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 328 studies in Cholangiocarcinoma with a site in United States — 72 open to participants now, 109 under way, 7 of them phase 3. Cholangiocarcinoma · United States.

Enrollment
243rd of 279
7 · median 44
Started
2023
with 20 others
Phase 1/2
42 of 328
12 open now
Registered
255th of 328
by date

Among the 328 studies in Cholangiocarcinoma with a site in United States, this one is the 243rd largest by enrollment of the 279 interventional ones that give a count, is one of 21 that started in 2023, is one of 42 in phase 1/2, and was the 255th registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

72 of the 328 studies in Cholangiocarcinoma with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 328 studies in Cholangiocarcinoma with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1/2 study evaluating the safety, tolerability, and activity of ivosidenib in combination with immunotherapy in participants with nonresectable or metastatic cholangiocarcinoma. The study includes two phases: the safety lead-in phase to determine the recommended combination dose (RCD) of ivosidenib in combination with immunotherapy and the dose expansion phase to assess the efficacy of ivosidenib in combination with immunotherapy. Study treatment will be administered until participant experiences unacceptable toxicity, disease progression, or other discontinuation criteria are met.

This study was terminated by the sponsor before the expansion phase began and therefore participants were only involved in the safety lead-in phase.

03

Conditions studied

  • IDH1-mutant Cholangiocarcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male of female participant age ≥ 18 years old
  • Have documented IDH1 gene-mutated disease based on local testing procedure (R132C/L/G/H/S mutations variants tested)
  • performance status (ECOG PS) score of 0 or 1
  • Has a histopathological diagnosis consistent with nonresectable or cholangiocarcinoma and are not eligible for curative resection, transplantation, or ablative therapies
  • Participants must have at least one as defined by Version 1.1. Subjects who have received prior local therapy (including but not limited to embolization, chemoembolization, radiofrequency ablation, or radiation therapy) are eligible provided measurable disease falls outside of the treatment field or if within the field but has shown ≥ 20% growth in size post-treatment assessment.

Exclusion criteria

Exclusion Criteria:

  • Received prior treatment with an IDH inhibitor or prior treatment with an other than anti-PD1/L1
  • Have active disease or any condition requiring systemic treatment with either (> 10 mg daily of prednisone equivalents) or other medications within 14 days of study treatment
  • Participants who have not recovered from toxicity of previous anticancer therapy, including Grade ≥ 1 non-hematologic toxicity, according to the National Cancer Institute v5.0, prior to the first IMP administration. Residual Grade ≤ 2 toxicity from chemotherapy (e.g., alopecia, neuropathy) may be allowed.
  • Have known symptomatic requiring steroids. Subjects with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study entry, have discontinued corticosteroid treatment for these for at least 4 weeks, and have radiographically stable disease for at least 3 months prior to study entry. Note: Up to 10 mg per day of prednisone equivalent will be allowed.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Safety Lead-In Phase - Ivosidenib 500mg

    Drug: Ivosidenib · Drug: Nivolumab · Drug: Ipilimumab

  • Experimental
    Safety Lead-In Phase - Ivosidenib 250mg

    Drug: Ivosidenib · Drug: Nivolumab · Drug: Ipilimumab

Interventions

  • ivosidenib taken once daily

  • Nivolumab taken by intravenous infusion

  • Ipilimumab taken by intravenous infusion

06

What researchers measure

Primary outcomes

  1. Safety Lead-In Phase: Number of Dose Limiting Toxicities (DLTs) Associated With Study Drug Regimen, During the First 2 Cycles of Treatment

    Occurring during the safety lead-in phase

    Time frame: Through the end of Cycle 2, day 42 (Cycle 1 and 2 are each 21 days)

  2. Safety Lead-In Phase: Number of Adverse Events (AEs)

    Occurring during the safety lead-in phase

    Time frame: Through study termination (approximately 1 year)

  3. Safety Lead-In Phase: Number of Participants With Adverse Events of Special Interests (AESIs)

    Occurring during the safety lead-in phase

    Time frame: Through study termination (approximately 1 year)

  4. Safety Lead-In Phase: Number of Serious Adverse Events (SAEs)

    Occurring during the safety lead-in phase

    Time frame: Through study termination (approximately 1 year)

Secondary outcomes

  1. Safety Lead-In Phase: Area Under the Concentration-vs-time Curve (AUC) From 0 to Time of Last Measurable Concentration (AUC0-t)

    Occurring during the safety lead-in phase

    Time frame: Up to 3 years

  2. Safety Lead-In Phase: Plasma 2-hydroxyglutarate (2-HG) Concentration

    Occurring during the safety lead-in phase

    Time frame: up to 3 years

  3. Safety Lead-In Phase: AUC Over 1 Dosing Interval at Steady State (AUCtau,ss)

    Occurring during the safety lead-in phase

    Time frame: Up to 3 years

  4. Safety Lead-In Phase: Time to Maximum Concentration (Tmax)

    Occurring during the safety lead-in phase

    Time frame: Up to 3 years

  5. Safety Lead-In Phase: Maximum Concentration (Cmax)

    Occurring during the safety lead-in phase

    Time frame: Up to 3 years

  6. Safety Lead-In Phase: Trough Concentration (Ctrough)

    Occurring during the safety lead-in phase

    Time frame: Up to 3 years

  7. Safety Lead-In Phase: Apparent Volume of Distribution (Vd/F)

    Occurring during the safety lead-in phase

    Time frame: Up to 3 years

  8. Safety Lead-In Phase: Apparent Clearance (CL/F)

    Occurring during the safety lead-in phase

    Time frame: Up to 3 years

07

Results

Posted Feb 12, 2026

Participant flow

Participant flow — Overall Study
MilestoneSafety Lead-In Phase - Ivosidenib 500mgSafety Lead-In Phase - Ivosidenib 250mg
Started43
Completed00
Not completed43
Withdrew: Withdrawal by subject01
Withdrew: Death32
Withdrew: Sponsor terminated the study10

Outcome measures

PrimarySafety Lead-In Phase: Number of Dose Limiting Toxicities (DLTs) Associated With Study Drug Regimen, During the First 2 Cycles of Treatment

Occurring during the safety lead-in phase

Time frame:
Through the end of Cycle 2, day 42 (Cycle 1 and 2 are each 21 days)
Reported as:
Number · DLT events
Safety Lead-In Phase: Number of Dose Limiting Toxicities (DLTs) Associated With Study Drug Regimen, During the First 2 Cycles of Treatment
DLT eventsSafety Lead-In Phase - Ivosidenib 500mgSafety Lead-In Phase - Ivosidenib 250mg
Safety Lead-In Phase: Number of Dose Limiting Toxicities (DLTs) Associated With Study Drug Regimen, During the First 2 Cycles of Treatment01
PrimarySafety Lead-In Phase: Number of Adverse Events (AEs)

Occurring during the safety lead-in phase

Time frame:
Through study termination (approximately 1 year)
Reported as:
Number · events
Safety Lead-In Phase: Number of Adverse Events (AEs)
eventsSafety Lead-In Phase - Ivosidenib 500mgSafety Lead-In Phase - Ivosidenib 250mg
Safety Lead-In Phase: Number of Adverse Events (AEs)7127
PrimarySafety Lead-In Phase: Number of Participants With Adverse Events of Special Interests (AESIs)

Occurring during the safety lead-in phase

Time frame:
Through study termination (approximately 1 year)
Reported as:
Count of participants · Participants
Safety Lead-In Phase: Number of Participants With Adverse Events of Special Interests (AESIs)
ParticipantsSafety Lead-In Phase - Ivosidenib 500mgSafety Lead-In Phase - Ivosidenib 250mg
Safety Lead-In Phase: Number of Participants With Adverse Events of Special Interests (AESIs)00
PrimarySafety Lead-In Phase: Number of Serious Adverse Events (SAEs)

Occurring during the safety lead-in phase

Time frame:
Through study termination (approximately 1 year)
Reported as:
Number · events
Safety Lead-In Phase: Number of Serious Adverse Events (SAEs)
eventsSafety Lead-In Phase - Ivosidenib 500mgSafety Lead-In Phase - Ivosidenib 250mg
Safety Lead-In Phase: Number of Serious Adverse Events (SAEs)32
SecondarySafety Lead-In Phase: Area Under the Concentration-vs-time Curve (AUC) From 0 to Time of Last Measurable Concentration (AUC0-t)

Occurring during the safety lead-in phase

Time frame:
Up to 3 years

No measurements were reported for this outcome.

SecondarySafety Lead-In Phase: Plasma 2-hydroxyglutarate (2-HG) Concentration

Occurring during the safety lead-in phase

Time frame:
up to 3 years

No measurements were reported for this outcome.

SecondarySafety Lead-In Phase: AUC Over 1 Dosing Interval at Steady State (AUCtau,ss)

Occurring during the safety lead-in phase

Time frame:
Up to 3 years

No measurements were reported for this outcome.

SecondarySafety Lead-In Phase: Time to Maximum Concentration (Tmax)

Occurring during the safety lead-in phase

Time frame:
Up to 3 years

No measurements were reported for this outcome.

SecondarySafety Lead-In Phase: Maximum Concentration (Cmax)

Occurring during the safety lead-in phase

Time frame:
Up to 3 years

No measurements were reported for this outcome.

SecondarySafety Lead-In Phase: Trough Concentration (Ctrough)

Occurring during the safety lead-in phase

Time frame:
Up to 3 years

No measurements were reported for this outcome.

SecondarySafety Lead-In Phase: Apparent Volume of Distribution (Vd/F)

Occurring during the safety lead-in phase

Time frame:
Up to 3 years

No measurements were reported for this outcome.

SecondarySafety Lead-In Phase: Apparent Clearance (CL/F)

Occurring during the safety lead-in phase

Time frame:
Up to 3 years

No measurements were reported for this outcome.

Adverse events

Collected over Through study termination (approximately 1 year). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Safety Lead-In Phase - Ivosidenib 500mg3/4 (75%)3/4 (75%)4/4 (100%)
Safety Lead-In Phase - Ivosidenib 250mg2/3 (66.7%)2/3 (66.7%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventSafety Lead-In Phase - Ivosidenib 500mgSafety Lead-In Phase - Ivosidenib 250mg
Immune-mediated dermatitisSkin and subcutaneous tissue disorders1/42/3
Immune-mediated hepatitisHepatobiliary disorders1/40/3
PyrexiaGeneral disorders1/40/3
Most frequent other events
Showing 10 of 50
Most frequent other events
EventSafety Lead-In Phase - Ivosidenib 500mgSafety Lead-In Phase - Ivosidenib 250mg
FatigueGeneral disorders4/41/3
DiarrhoeaGastrointestinal disorders3/41/3
Immune-mediated dermatitisSkin and subcutaneous tissue disorders3/41/3
PruritusSkin and subcutaneous tissue disorders3/40/3
Malignant ascitesGastrointestinal disorders0/42/3
NauseaGastrointestinal disorders2/41/3
Dry mouthGastrointestinal disorders2/40/3
Oedema peripheralGeneral disorders2/40/3
CoughRespiratory, thoracic and mediastinal disorders2/41/3
DyspnoeaRespiratory, thoracic and mediastinal disorders2/41/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)Safety Lead-In Phase - Ivosidenib 500mgSafety Lead-In Phase - Ivosidenib 250mgTotal
Mean60.8 ± 20.6149.3 ± 15.3755.9 ± 18.12
Age, Customized
Age, Customized(Participants)Safety Lead-In Phase - Ivosidenib 500mgSafety Lead-In Phase - Ivosidenib 250mgTotal
< 65 years224
≥ 65 years213
Sex: Female, Male
Sex: Female, Male(Participants)Safety Lead-In Phase - Ivosidenib 500mgSafety Lead-In Phase - Ivosidenib 250mgTotal
Female437
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Safety Lead-In Phase - Ivosidenib 500mgSafety Lead-In Phase - Ivosidenib 250mgTotal
Asian101
White336
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Safety Lead-In Phase - Ivosidenib 500mgSafety Lead-In Phase - Ivosidenib 250mgTotal
Not Hispanic or Latino336
Missing101
Region of Enrollment
Region of Enrollment(participants)Safety Lead-In Phase - Ivosidenib 500mgSafety Lead-In Phase - Ivosidenib 250mgTotal
United States415
United Kingdom022
BMI
BMI(kg/m^2)Safety Lead-In Phase - Ivosidenib 500mgSafety Lead-In Phase - Ivosidenib 250mgTotal
Mean26.80 ± 6.34723.33 ± 2.11425.31 ± 5.007
08

Study locations

5 sites
  • UCSF - Medical Center at Mission Bay
    San Francisco, California 94158, United States
  • Ucsf Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94158, United States
  • Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
    Baltimore, Maryland 21231, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • UCLH
    London, NW1 2PG, United Kingdom
09

References and documents

Publications

  • Kelley RK, Cleary JM, Sahai V, Baretti M, Bridgewater JA, Hua Z, Gliser C, Bian Y, Abou-Alfa GK. A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma. J Clin Oncol. 2024 May 29;42(16_Supplement):TPS4197. doi: https://doi.org/10.1200/JCO.2024.42.16_suppl.TPS4197

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

Supporting information: Study protocol, Statistical analysis plan

Time frame: After Marketing Authorization in EEA or US if the study is used for the approval.

Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

Data sharing details ↗ · clinicaltrials.servier.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Nov 2024, 12 months.

Results were first posted in Feb 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2023
First posted
Jun 27, 2023
StartActual
Oct 23, 2023
Primary completionActual
Nov 21, 2024
CompletionActual
Nov 21, 2024
Results first posted
Feb 12, 2026
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05921760
Lead sponsor
Servier Bio-Innovation LLC
Collaborators
Institut de Recherches Internationales Servier
Responsible party
Sponsor
First posted
Jun 27, 2023
Start date
Oct 23, 2023
Primary completion
Nov 21, 2024
Completion
Nov 21, 2024
Results posted
Feb 12, 2026
Last update
Apr 20, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ivosidenib · Nivolumab

Start the discussion